49 related articles for article (PubMed ID: 27788476)
1. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients.
Fang C; Wang FB; Li Y; Zeng XT
Biomed Pharmacother; 2016 Dec; 84():1189-1193. PubMed ID: 27788476
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.
Bitaraf A; Babashah S; Garshasbi M
J Clin Lab Anal; 2020 Feb; 34(2):e23063. PubMed ID: 31595567
[TBL] [Abstract][Full Text] [Related]
3. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family.
Ye F; Tang H; Liu Q; Xie X; Wu M; Liu X; Chen B; Xie X
J Transl Med; 2014 Jan; 12():17. PubMed ID: 24447584
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between miR-497-5p Expression With Clinicopathological Characteristics and Prognosis in Patients With Breast Cancer.
Zhang Z; Zhou Y; Liang S
Appl Immunohistochem Mol Morphol; 2024 Apr; 32(4):200-205. PubMed ID: 38497335
[TBL] [Abstract][Full Text] [Related]
5. Expression and Significance of LINC02418 in Breast Cancer.
Zhou YH; Huang JY
Breast Cancer (Dove Med Press); 2024; 16():233-243. PubMed ID: 38694704
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer cell-secreted miR-199b-5p hijacks neurometabolic coupling to promote brain metastasis.
Ruan X; Yan W; Cao M; Daza RAM; Fong MY; Yang K; Wu J; Liu X; Palomares M; Wu X; Li A; Chen Y; Jandial R; Spitzer NC; Hevner RF; Wang SE
Nat Commun; 2024 May; 15(1):4549. PubMed ID: 38811525
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of
Huang Y; Jian W; Zhao J; Wang G
Onco Targets Ther; 2018; 11():2177-2184. PubMed ID: 29713186
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognosis analysis of integrin subunit α3 (ITGA3) in papillary thyroid cancer.
Ma JJ; Xiang C; Zhu HQ; Bai BL; Wang P; Zhao GA
Heliyon; 2024 Jan; 10(1):e23163. PubMed ID: 38163190
[TBL] [Abstract][Full Text] [Related]
9. Expression of miR-221 in colon cancer correlates with prognosis.
Cai K; Shen F; Cui JH; Yu Y; Pan HQ
Int J Clin Exp Med; 2015; 8(2):2794-8. PubMed ID: 25932237
[TBL] [Abstract][Full Text] [Related]
10.
Zhou Y; Xue W; Meng X; Bhandari A; Zeng H; Kc R; Hirachan S; Xia E
Breast Cancer (Dove Med Press); 2024; 16():71-89. PubMed ID: 38476642
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical diagnostic value of CCHE1 in breast cancer.
Zhao F; Zhou W; Xin R; Miao X
Mutagenesis; 2024 Mar; 39(2):141-145. PubMed ID: 38150355
[TBL] [Abstract][Full Text] [Related]
12. Historical trends of breast cancer burden attributable to metabolic factors among Chinese women, 1990-2019: A population-based epidemiological study.
Zhang LZ; Sun QC; Luan HH; Yuan QQ; Deng T; Luo LS; Tan XL
Thorac Cancer; 2024 Jun; 15(16):1279-1286. PubMed ID: 38664975
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study.
Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974
[TBL] [Abstract][Full Text] [Related]
14. Multi-Drug Resistance against Second-Line Medication and MicroRNA Plasma Level in Metastatic Breast Cancer Patients.
Dehghani M; Mokhtari S; Abidi H; Alipoor B; Nazer Mozaffari MA; Sadeghi H; Mahmoudi R; Nikseresht M
Iran J Med Sci; 2023 Mar; 48(2):146-155. PubMed ID: 36895459
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents.
Wang ZH; Zheng ZQ; Jia SC; Liu SN; Xiao XF; Chen GY; Liang WQ; Lu XF
Front Oncol; 2022; 12():1006429. PubMed ID: 36276152
[TBL] [Abstract][Full Text] [Related]
16. Angioregulatory microRNAs in breast cancer
Soheilifar MH; Masoudi-Khoram N; Madadi S; Nobari S; Maadi H; Keshmiri Neghab H; Amini R; Pishnamazi M
J Adv Res; 2022 Mar; 37():235-253. PubMed ID: 35499045
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.
Dayakar A; Shanmukha KD; Kalangi SK
Mol Biol Rep; 2022 Jul; 49(7):6827-6846. PubMed ID: 35031927
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque M; Sanz-Álvarez M; Santamaría A; Zazo S; Cristóbal I; de la Fuente L; Mínguez P; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948097
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.
Stempor PA; Avni D; Leibowitz R; Sidi Y; Stępień M; Dzieciątkowski T; Dobosz P
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806327
[TBL] [Abstract][Full Text] [Related]
20. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
